Neuroscience
Modifying the microbiota could influence multiple sclerosis progression and provide new therapeutic targets.
MaaT Pharma’s venture marks an innovative and hopeful chapter in the ongoing effort to fight neurodegeneration.
Gut microbiota-produced bile acids can be used as therapeutic targets for multiple sclerosis.
Treatment with the probiotic Lactobacillus murinus improved social behavior and partially restored gut and brain function.
Emil Chuang, Chief Medical Officer at Intrinsic Medicine, explores the growing understanding of gut-brain axis disorders and the potential of Human Milk Oligosaccharides (HMOs) in their treatment.
A study revealed a link between gut microbiota composition and brain development in preterm infants, suggesting that specific bacteria and their metabolites can influence neurodevelopment.
New research has now uncovered differences in the gut microbiota composition between people with the condition and those without.
The findings suggest that gut microbes and LPC are potential therapeutic targets for Alzheimer's disease.
A significant milestone for both microbiome research and neurodegenerative diseases.
New microbiome based therapy demonstrates safety and potential benefits for liver cirrhosis and mental health.
